Linvencorvir

Linvencorvir (RG7907) is an orally active Hepatitis B virus core protein allosteric modulator. Linvencorvir induces Apoptosis. Linvencorvir has antiviral activity against HBV[1][2][3][4][5][6].

Product Specifications

CAS Number

[1808248-05-6]

Product Name Alternative

RG7907; RO7049389

UNSPSC

12352005

Target

Apoptosis; HBV

Type

Reference compound

Related Pathways

Anti-infection; Apoptosis

Applications

COVID-19-anti-virus

Field of Research

Infection; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/linvencorvir.html

Purity

98.14

Solubility

DMSO : 62.5 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

CCOC(C1=C(CN2C[C@]3([H])N(C(N(C3)CC(C)(C)C(O)=O)=O)CC2)N=C(C4=NC=CS4)N[C@@]1([H])C5=C(C(F)=CC=C5)C)=O

Molecular Formula

C29H35FN6O5S

Molecular Weight

598.69

References & Citations

[1]Vanrusselt H, et al. Novel non-HAP class A HBV capsid assembly modulators have distinct in vitro and in vivo profiles. J Virol. 2023 Oct 31;97 (10) :e0072223.|[2]Zhang Y, et al. Evaluation of the drug disposition of RO7049389 with in vitro data and human mass balance supported by physiologically based pharmacokinetic modelling. Br J Clin Pharmacol. 2023 Oct;89 (10) :3079-3091.|[3]Zhang W, et al. Discovery of Linvencorvir (RG7907), a Hepatitis B Virus Core Protein Allosteric Modulator, for the Treatment of Chronic HBV Infection. J Med Chem. 2023 Mar 23;66 (6) :4253-4270.|[4]Kum DB, et al. Class A capsid assembly modulator RG7907 clears HBV-infected hepatocytes through core-dependent hepatocyte death and proliferation. Hepatology. 2023 Oct 1;78 (4) :1252-1265. |[5]Feng S, et al. A Five-in-One First-in-Human Study To Assess Safety, Tolerability, and Pharmacokinetics of RO7049389, an Inhibitor of Hepatitis B Virus Capsid Assembly, after Single and Multiple Ascending Doses in Healthy Participants. Antimicrob Agents Chemother. 2020 Oct 20;64 (11) :e01323-20.|[6]Yang L, et al. Treatment of Chronic Hepatitis B Virus Infection Using Small Molecule Modulators of Nucleocapsid Assembly: Recent Advances and Perspectives. ACS Infect Dis. 2019 May 10;5 (5) :713-724.